<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> arises through well-defined precursor lesions (<z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo>), although only a subset of these lesions advances to invasive <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>The lack of markers predicting progression in <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo>, typical presentation at advanced stage, and limitations of conventional chemotherapy result in &gt;90% mortality for Barrett-associated <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>To identify potential prognostic markers and therapeutic targets, we compared gene expression profiles from Barrett-associated esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> cell lines (BIC1, SEG1, KYAE, OE33) and <z:mpath ids='MPATH_458'>normal</z:mpath> esophageal epithelial scrapings utilizing the Affymetrix U133_A gene expression platform </plain></SENT>
<SENT sid="3" pm="."><plain>We identified 560 transcripts with &gt;3-fold up-regulation in the <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> cell lines compared with <z:mpath ids='MPATH_458'>normal</z:mpath> epithelium </plain></SENT>
<SENT sid="4" pm="."><plain>Utilizing tissue microarrays composed of <z:mpath ids='MPATH_458'>normal</z:mpath> esophageal squamous mucosa (n = 20), <z:hpo ids='HP_0100580'>Barrett esophagus</z:hpo> (n = 10), low-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (n = 14), high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (n = 27), <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (n = 59), and node <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> (n = 27), we confirmed differential up-regulation of three proteins (Cdc2/Cdk1, Cdc5, and Igfbp3) in <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> and Barrett lesions </plain></SENT>
<SENT sid="5" pm="."><plain>Protein expression mirrored histologic progression; thus, 87% of low-grade <z:mpath ids='MPATH_589'>dysplasias</z:mpath> had at least focal surface Cdc2/Cdk1 and 20% had &gt;5% surface staining; 96% of high-grade <z:mpath ids='MPATH_589'>dysplasias</z:mpath> expressed abundant surface Cdc2/Cdk1, while invasive <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> demonstrated ubiquitous expression </plain></SENT>
<SENT sid="6" pm="."><plain>Esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> cell lines treated with the novel CDC2/CDK1 transcriptional inhibitor, tetra-O-<z:chebi fb="36" ids="29309">methyl</z:chebi> nordihydroguaiaretic acid (EM-1421, formerly named M4N) demonstrated a dose-dependent reduction in cell proliferation, paralleling down-regulation of CDC2/CDK1 transcript and protein levels </plain></SENT>
<SENT sid="7" pm="."><plain>These findings suggest a role for CDC2/CDK1 in esophageal adenocarcinogenesis, both as a potential histopathologic marker of <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and a putative treatment target </plain></SENT>
</text></document>